Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected Patients.
Detection of Hepatitis B Virus-Host Junction Sequences in Urine of Infected Patients.
复制标题
感染患者尿液中乙肝病毒-宿主连接序列的检测
DOI:
10.1002/hep4.1783
复制
发表时间:
2021-10
影响因子:
5.1
通讯作者:
Su YH
中科院分区:
文献类型:
--
作者:
Lin SY;Su YP;Trauger ER;Song BP;Thompson EGC;Hoffman MC;Chang TT;Lin YJ;Kao YL;Cui Y;Hann HW;Park G;Shieh FS;Song W;Su YH
Integrated hepatitis B virus (HBV) DNA, found in more than 85% of HBV‐associated hepatocellular carcinomas (HBV‐HCCs), can play a significant role in HBV‐related liver disease progression. HBV‐host junction sequences (HBV‐JSs), created through integration events, have been used to determine HBV‐HCC clonality. Here, we investigate the feasibility of analyzing HBV integration in a noninvasive urine liquid biopsy. Using an HBV‐targeted next‐generation sequencing (NGS) assay, we first identified HBV‐JSs in eight HBV‐HCC tissues and designed short‐amplicon junction‐specific polymerase chain reaction assays to detect HBV‐JSs in matched urine. We detected and validated tissue‐derived junctions in five of eight matched urine samples. Next, we screened 32 urine samples collected from 25 patients infected with HBV (5 with hepatitis, 10 with cirrhosis, 4 with HCC, and 6 post‐HCC). Encouragingly, all 32 urine samples contained HBV‐JSs detectable by HBV‐targeted NGS. Of the 712 total HBV‐JSs detected in urine, 351 were in gene‐coding regions, 11 of which, including TERT (telomerase reverse transcriptase), had previously been reported as recurrent integration sites in HCC tissue and were found only in the urine patients with cirrhosis or HCC. The integration breakpoints of HBV DNA detected in urine were found predominantly (~70%) at a previously identified integration hotspot, HBV DR1‐2 (down‐regulator of transcription 1‐2). Conclusion: HBV viral–host junction DNA can be detected in urine of patients infected with HBV. This study demonstrates the potential for a noninvasive urine liquid biopsy of integrated HBV DNA to monitor patients infected with HBV for HBV‐associated liver diseases and the efficacy of antiviral therapy.
登录
查看更多内容
影响因子:
6.2
作者:
Chauhan R;Churchill ND;Mulrooney-Cousins PM;Michalak TI
通讯作者:
Michalak TI
DOI:
10.1002/hep.31503
发表时间:
2020-11
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
Fergusson JR;Wallace Z;Connolly MM;Woon AP;Suckling RJ;Hine DW;Barber C;Bunjobpol W;Choi BS;Crespillo S;Dembek M;Dieckmann N;Donoso J;Godinho LF;Grant T;Howe D;McCully ML;Perot C;Sarkar A;Seifert FU;Singh PK;Stegmann KA;Turner B;Verma A;Walker A;Leonard S;Maini MK;Wiederhold K;Dorrell L;Simmons R;Knox A
通讯作者:
Knox A
影响因子:
25.7
作者:
Li, Xiaojun;Zhang, Jiangbo;Lu, Fengmin
通讯作者:
Lu, Fengmin
影响因子:
7
作者:
Jiang, Zhaoshi;Jhunjhunwala, Suchit;Zhang, Zemin
通讯作者:
Zhang, Zemin
影响因子:
3.8
作者:
El Kramani, Nabila;Elsherbiny, Nehal M.;Al-Gayyar, Mohammed M. H.
通讯作者:
Al-Gayyar, Mohammed M. H.